First-Line Treatment for Intermediate and Poor Risk Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Michael T Serzan; Wenxin Xu; Stephanie A Berg

doi:10.1016/j.hoc.2023.04.018

First-Line Treatment for Intermediate and Poor Risk Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Hematol Oncol Clin North Am. 2023 Oct;37(5):951-964. doi: 10.1016/j.hoc.2023.04.018. Epub 2023 May 29.

Authors

Michael T Serzan¹, Wenxin Xu¹, Stephanie A Berg²

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street D1230, Boston, MA 02115, USA.
² Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street D1230, Boston, MA 02115, USA. Electronic address: stephaniea_berg@dfci.harvard.edu.

PMID: 37258355
DOI: 10.1016/j.hoc.2023.04.018

Abstract

Combination therapies with immune checkpoint blockers have shown improvements in overall response rate, progression free survival, and overall survival over monotherapy with sunitinib in intermediate and poor risk subgroups. Identification of best upfront therapy may be guided by future clinical trials utilizing adaptive strategies, triplet therapy, or novel biomarkers.

Keywords: Clear cell renal cell carcinoma; IMDC intermediate and poor risk; Immune checkpoint inhibitors; Vascular endothelial growth factor receptor tyrosine kinase inhibitor.

Publication types

Review

MeSH terms

Carcinoma, Renal Cell* / drug therapy
Carcinoma, Renal Cell* / pathology
Humans
Kidney Neoplasms* / drug therapy
Progression-Free Survival
Protein Kinase Inhibitors / therapeutic use
Sunitinib / therapeutic use

Substances

Sunitinib
Protein Kinase Inhibitors

Supplementary concepts

Clear-cell metastatic renal cell carcinoma